Vigil Neuroscience, Inc. (VIGL) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
VIGL currently has 46.1M outstanding shares. with moderate dilution risk from 18.3M authorized shares representing 39.8% potential dilution. The company has diluted shareholders by 18.42% over the past 2 years through share issuances.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| Aug 05, 2025 |
POS AM filing: This POS AM filing deregisters securities due to the merger between Vigil Neuroscience, Inc. and Sanofi, terminating all existing offerings under previous registration statements. |
46M | 18M |
| Aug 05, 2025 |
POS AM filing: This POS AM filing indicates the deregistration of securities due to the merger of Vigil Neuroscience, Inc. with a subsidiary of Sanofi, leading to the termination of all existing offerings and the removal of unsold registered securities. |
46M | 49M |
| Aug 05, 2025 |
10-Q filing | 47.6M shares outstanding |
48M | 54M |
| May 07, 2025 |
10-Q filing | 46.1M shares outstanding |
46M | 54M |
| Mar 31, 2025 |
S-3 filing: The selling stockholder may offer and sell up to 5,376,340 shares of common stock issuable upon the conversion of 537,634 shares of Series A Preferred Stock. |
47M | 54M |
| Mar 13, 2025 |
10-K filing | 46.7M shares outstanding |
47M | 49M |
| Nov 07, 2024 |
10-Q filing | 40.6M shares outstanding |
41M | 49M |
| Aug 13, 2024 |
10-Q filing | 40.6M shares outstanding |
41M | 49M |
| May 07, 2024 |
10-Q filing | 39.9M shares outstanding |
40M | 49M |
| Mar 26, 2024 |
10-K filing | 38.7M shares outstanding |
39M | 49M |
| Nov 07, 2023 |
10-Q filing | 38.8M shares outstanding |
39M | 49M |
| Aug 08, 2023 |
10-Q filing | 38.7M shares outstanding |
39M | 49M |
| May 10, 2023 |
10-Q filing | 38.5M shares outstanding |
39M | 49M |
| Mar 21, 2023 |
10-K filing | 35.6M shares outstanding |
36M | 49M |
| Mar 21, 2023 |
S-3 filing: Vigil Neuroscience files an S-3 form on 2023-03-21 for a shelf offering of common stock, preferred stock, and debt securities, with a total proposed amount of $300,000,000. Additionally, there is an offering of common stock through Jefferies LLC, acting as a sales agent, with an aggregate offering price of up to $100,000,000. |
33M | 49M |
| Nov 10, 2022 |
10-Q filing | 33.3M shares outstanding |
33M | 18M |
| Sep 30, 2022 |
S-1 filing: This S-1 filing relates to the proposed resale or other disposition by the selling stockholders of 10,273,973 shares of common stock, consisting of shares of our common stock, and pre-funded warrants to purchase shares of our common stock. |
28M | 18M |
| Aug 08, 2022 |
10-Q filing | 28.3M shares outstanding |
28M | 8.1M |
| May 12, 2022 |
10-Q filing | 28.3M shares outstanding |
28M | 8.1M |
| Jan 03, 2022 |
S-1/A filing: This S-1/A filing is for an initial public offering of common stock. The company intends to use the net proceeds from this offering to advance the development of VGL101, for the continued research of our novel, small molecule program and development programs, and for working capital and other general corporate purposes. |
28M | 8.1M |